Filana Therapeutics
FLNA
143 hedge funds and large institutions have $236M invested in Filana Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 25 closing their positions.
40% more call options, than puts
Call options by funds: $46M | Put options by funds: $32.9M
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.31% less ownership
Funds ownership: 33.17% → 26.86% (-6.3%)
7% less funds holding
Funds holding: 153 → 143 (-10)
25% less capital invested
Capital invested by funds: $315M → $236M (-$79.1M)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$734K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$642K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$613K |
| 4 |
State Street
Boston,
Massachusetts
|
+$549K |
| 5 |
PI
PFG Investments
Woodbury,
New York
|
+$504K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$11.3M |
| 2 |
Morgan Stanley
New York
|
-$7.76M |
| 3 |
Jane Street
New York
|
-$6.4M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$5.97M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$2.68M |
FLNA Hedge Fund Activity: Q1 2024 in Review
143 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q1 2024, worth a combined $236M — down 25% from $315M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of FLNA and 15 opened new positions — a net loss of 10 holders — while 43 trimmed existing stakes and 47 added.
The largest buyer was Vanguard Group, adding an estimated $734K. The largest seller was Cowen and Company, exiting entirely with an estimated $11.3M sold.
- 143 institutional investors held Filana Therapeutics (FLNA) as of Q1 2024, down from 153 in Q4 2023.
- Funds reported $236M of Filana Therapeutics stock for Q1 2024, down 25% quarter-over-quarter.
- 15 funds opened new Filana Therapeutics positions in Q1 2024 and 25 closed out, a net change of -10 holders.
- The largest Filana Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $734K added.
- The largest Filana Therapeutics seller in Q1 2024 was Cowen and Company, an estimated $11.3M sold.
Based on aggregated 13F filings for Q1 2024.